02937nam 2200709 450 991078759350332120230803030605.01-78084-327-51-78084-222-8(CKB)2670000000391297(EBL)1179652(OCoLC)851970667(SSID)ssj0001599936(PQKBManifestationID)16306450(PQKBTitleCode)TC0001599936(PQKBWorkID)14892880(PQKB)10368831(SSID)ssj0001599982(PQKBManifestationID)16306727(PQKBTitleCode)TC0001599982(PQKBWorkID)14892444(PQKB)11405068(MiAaPQ)EBC5092475(MiAaPQ)EBC1179652(Au-PeEL)EBL5092475(CaPaEBR)ebr11451923(OCoLC)851776810(Au-PeEL)EBL1179652(EXLCZ)99267000000039129720220517d2013 uy 0engur|n|---|||||txtccrMonoclonal antibodies in oncology /editor, Fatih M. Uckun1st ed.London, England :Future Medicine Ltd.,[2013]©20131 online resource (85 p.)Future Medecine,2047-332XDescription based upon print version of record.1-78084-329-1 1-78084-224-4 Includes bibliographical references at the end of each chapters and index.Title page; Copyright page; Contents; Foreword. Monoclonal antibodies in contemporary cancer therapy; 1. mAbs targeting CD20 and other lymphocyte CD markers in lymphoma treatment; 2. mAbs targeting CTLA-4 and clinical outcomes; 3. mAbs targeting VEGF/VEGFR and clinical outcomes in cancer treatment; 4. mAbs targeting RANKL in bone metastasis treatment; 5. Novel monoclonal antibody-based therapies for leukemia; IndexMonoclonal antibodies (mAbs) have been developed to improve the treatment outcome of cancer patients undergoing therapy according to multimodality regimens without a significant increase of treatment-associated toxicity. This five-chapter book provides examples where mAbs that have become part of the standard of care in cancer patients and cancer types that have responded to mAbsMonoclonal antibodiesTherapeutic useAntibody-toxin conjugatesTherapeutic useCancerImmunotherapyMonoclonal antibodiesTherapeutic use.Antibody-toxin conjugatesTherapeutic use.CancerImmunotherapy.615.37Uckun Fatih M.MiAaPQMiAaPQMiAaPQBOOK9910787593503321Monoclonal antibodies in oncology3730107UNINA